In a multivariable regression analysis including gender, TIMI risk score and renal dysfunction, both TIMI risk score (OR = 1.47, 95% CI 1.35-1.60) and renal dysfunction (OR 2.71, 95% CI 1.56-4.69) were strong predictors of in-hospital mortality; there was a trend towards higher mortality in women (OR 1.45, 95% CI 0.8-2.63).
For example, patients with kidney dysfunction or known risk factors for osteonecrosis of the jaw may not be candidates for bisphosphonate therapy.
Cardiovascular is defined as studies meeting search criteria for conditions involving coronary artery disease, cardiac dysfunction, or known risk factors for the above such as hypercholesterolemia and hypertension.
The groups of patients with no kidney dysfunction or at risk of kidney injury on admission who received HES were more severely ill; in particular, they had more cardiovascular and respiratory failures.
The probability to choose for a specific PC treatment (i.e., AS or radiotherapy with 5% risk of permanent urinary incontinence and 25% risk of erectile dysfunction, or surgery with 20% risk of permanent urinary incontinence and 45% risk of erectile dysfunction) showed a substantial difference between the patient groups.
In normotensive patients without signs of right ventricular dysfunction or damage, the risk of mortality and of PE-related complication is low and the use of thrombolytic treatment is not indicated, in part because of its associated bleeding risk [15].
Regardless of whether elevated SUA is solely a marker of subclinical chronic renal dysfunction or an independent risk factor for the development of CKD, careful attention is warranted.
The necessity and urgency of treatment oft en depends on the involvement of vital organs and risk of organ dysfunction or failure, although this risk is not currently defined.
The main goal of the current study was to identify comorbid genes whose dysfunction or mutation represent common risk factors for diseases that are concurrent with PE.
Taurolidine-citrate solution failed to decrease significantly the risk of CR-BSI (1.4 vs. 2.4 episodes/1,000 catheter-days, P = 0.1) but increased the risk of dysfunction or thrombosis requiring thrombolytic treatment [ 93].
